Julia V. Cockle

TL;DR: It is shown, in a window-of-opportunity clinical study, that intravenous infusion of oncolytic human Orthoreovirus leads to infection of tumor cells subsequently resected as part of standard clinical care, both in high-grade glioma and in brain metastases, and increases cytotoxic T cell tumor infiltration relative to patients not treated with virus.

TL;DR: The findings support clinical application of VSV-TAA therapy with checkpoint inhibition for aggressive brain tumors and highlight the importance of the intracranial microenvironment in sculpting a location-specific profile of tumor antigen expression.

TL;DR: This is the first study to demonstrate that it is possible to pharmacologically target migration of paediatric glioma in vitro using LiCl and BIO, and it is concluded that these agents and their derivatives warrant further preclinical investigation as potential anti-migratory therapeutics for these devastating tumours.

TL;DR: It is demonstrated that HSV1716 targets the migration and invasion of pHGG and DIPG and indicates the potential of an oncolytic virus to be used as a novel anti-invasive treatment strategy for pediatric brain tumors.

TL;DR: A novel and reproducible method for high content analysis of invading cells using multicellular tumour spheroid assays in a high grade glioma model allows researchers to perform screening of anti-tumour invasion compounds and study their effects on cellular dynamics, particularly in relation to protein expression, for the first time.